BLISS GVS PHARMA LTD.



October 29, 2024

To

The Manager, Listing Department National Stock Exchange of India Ltd.

Plot no. C/1 G Block,

Bandra-Kurla Complex, Bandra (East),

Mumbai- 400 051

Symbol: BLISSGVS

To

The General Manager, Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400 001

Scrip Code: 506197

Dear Sir/Madam,

Sub: Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 by Promoter of the Company

This is to inform you that, pursuant to the Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 2011, the Company has received disclosure from Mr. Narsimha Shibroor Kamath, Promoter of the Company regarding the acquisition of 1,80,000 shares and 2,00,000 shares of Bliss GVS Pharma Limited through the open market on October 28, 2024, and October 29, 2024, respectively.

This is for your information and record.

Thanking you.

Yours Faithfully,

For Bliss GVS Pharma Limited

Company Secretary

Encl: a/a

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory: Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com

To,	То,	To,		
Corporate Relationship Dept., BSE Limited,	Listing Department, National Stock Exchange of	Bliss GVS Pharma Limited 102, Hyde Park, Saki Vihar		
Phiroze Jeejeebhoy Towers,	India Ltd.,	Road, Andheri (East).		
Dalal Street,	Exchange Plaza, C-1, Block G,	Mumbai - 400072.		
Mumbai-400001.	Bandra Kurla Complex,			
Scrip Code: 506197	Bandra (E). Mumbai-400 051			
	Symbol: BLISSGVS			

Dear Sir/Madam,

<u>Subject: Disclosure pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011</u>

Enclosed herewith the disclosure as required in terms of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended from time to time, regarding the acquisition of 1,80,000 shares and 2,00,000 shares of Bliss GVS Pharma Limited through the open market on October 28, 2024, and October 29, 2024, respectively.

Kindly acknowledge receipt of the same.

5.20.10pm

Thanking You,

Narsimha Shibroor Kamath

Promoter

Encl: a/a

<u>Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011</u>

Shares and Takeovers) Regulations, 2011						
Name of the Target Company (TC)	ame of the Target Company (TC) Bliss GVS Pharma Limited					
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer - Mr. Narsimha Shibroor Kamath Persons Acting in Concert (PAC) - Mrs. Shruti Vishal Rao Dr. Vibha Gagan Sharma Mr. Gagan Harsh Sharma Mr. Shibroor Gokuldas Kamath Mr. Ramadas Vasudev Kamath Ms. Punita Sharma Ramadas Vasudev Kamath HUF					
Whether the acquirer belongs to Promoter / Promoter group	Yes					
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	The BSE Limited and National Stock Exchange of India Limited					
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)			
Before the acquisition under consideration, holding of:						
a) Shares carrying voting rightsb) Shares in the nature of	3,19,57,024	30.39%	NA			
encumbrance (pledge/ lien/ non- disposal undertaking/ others)	NIL	NIL	NIL			
b) Voting rights (VR) otherwise than by shares	NIL	NIL	NIL			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	NIL	NIL	NIL			
e) Total (a+ b+ c+ d)	3,19,57,024	30.39%	NA			
Details of acquisition/sale						
a) Shares carrying voting rights acquired / sold	3,80,000	0.36%	NA			
b) VRs acquired /sold otherwise than by shares	NIL	NIL	NIL			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	NIL	NIL	NIL			
d) Shares encumbered/invoked / released by the acquirer	NIL	NIL	NIL			
e) Total (a+ b+ c+/-d)	3,80,000	0.36%	NA			

After the acquisition / sale, holding of:			
a) Shares carrying voting rights acquired	3,23,37,024	30.75%	NA
b) Shares encumbered with the acquirer	NIL	NIL	NIL
c) VRs otherwise than by shares	NIL	NIL	NIL
d) Warrants / convertible securities /			
any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding		NIL	NIL
in each category) after acquisition			
e) Total (a+b+c+d)	3,23,37,024	30.75%	NA
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open Market		
Date of acquisition / sale of shares / VR or			
date of receipt of intimation of allotment of shares, whichever is applicable			
Equity share capital/total voting capital of the TC before the said acquisition/sale	Rs. 10,51,44,472/-		
Equity share capital/ total voting capital of the TC after the said acquisition/sale	Rs. 10,51,44,472/-		
Total diluted share/voting capital of the TC after the said acquisition	NA		

(*) Total share capital/voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

5.00-100m.

Signature of the acquirer Narsimha Shibroor Kamath

Place: Mumbai

Date: October 29, 2024
